Anne Kingston

Maclean's Senior writer

Senior Writer Anne Kingston covers contemporary culture—everything from medical politics to the politics of food. She is the author of 'The Meaning of Wife: A Provocative Look at Women and Marriage in the 21st Century' and 'The Edible Man: Dave Nichol, President’s Choice and the Making of Popular Taste.' Find her at anne.kingston@macleans.rogers.com.

A research assistant prepares syringes inside a pharmacy glovebox at the reversible inhibition of sperm under guidance (RISUG) male contraceptive treatment research and development laboratory at Indian Institute of Technology (IIT) Kharagpur in Kharagpur, West Bengal, India, on Feb. 16, 2017. A new birth control method for men has the potential to win as much as half the $10 billion market for female contraceptives worldwide and cut into the $3.2 billion of annual condom sales, businesses dominated by pharmaceutical giants Bayer AG, Pfizer Inc. and Merck & Co., according to estimates from the last major drug company to explore the area. (Sumit Dayal/Bloomberg/Getty Images)
A father with his children. (Maskot/Getty Images)